FDA Clears Ranbaxy U.S. Subsidiary of cGMP Violations

Ranbaxy enjoyed some recent good news when its U.S. subsidiary resolved FDA current good manufacturing practice (cGMP) violations resulting from a 2012 inspection. The resolution came in the form of an establishment inspection report (EIR) to Ohm Laboratories, which manages Ranbaxy’s facility responsible for supplying a majority of the Indian drugmaker’s prescription and OTC products in the U.S. Ranbaxy’s Indian facilities remain under an FDA import alert.
Drug Industry Daily